Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jan 12, 2021 9:11pm
228 Views
Post# 32282241

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Excellent

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ExcellentI will say it again. I don't like the deal, I was not expecting it two days after the news, so I understand the frustrations. That being said, I don't think management and board are fools. Also, if you are in this stock for the long run, believing in the two clinical programs, dilution should not disturb you that much because there will be a good way to counter that at some point if they end up with positive results in one trial or both. If there is real clinical success, the SP will rise too much at some point, like when it went to 14$ after approval of Trogarzo. A way to compensate for the dilution will be to sell when the market will be irrationally positive. If both trial are failures, then dilution will not mean much. So if you believed in the two clinical programs, it means that if you are right, there will be an exit point that will compensate for the dilution, and remember that selling at a high point does not prevent you to buy it back later.
<< Previous
Bullboard Posts
Next >>